文 献1）De S, Kuwahara S, Saito A. The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells. Membranes (Basel) 2014; 4(3): 333-55.2）Kuwahara S, Hosojima M, Kaneko R, Aoki H, Nakano D, Sasagawa T, et al. Megalin-mediated tubuloglomerular alterations in high-fat diet-induced kidney disease. J Am Soc Nephrol 2016; 27(7): 1996-2008.3）Ogasawara S, Hosojima M, Kaseda R, Kabasawa H, Yamamoto-Kabasawa K, Kurosawa H, et al. Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes. Diabetes Care 2012; 35(5): 1112-8.4）Kalani A, Mohan A, Godbole MM, Bhatia E, Gupta A, Sharma RK, et al. Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLoS One 2013; 8(3): e60177.5）Sun AL, Deng JT, Guan GJ, Chen SH, Liu YT, Cheng J, et al. Dipeptidyl peptidase-Ⅳ is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res 2012; 9(4): 301-8.6）De S, Kuwahara S, Hosojima M, Ishikawa T, Kaseda R, Sarkar P, et al. Exocytosis-mediated urinary full-length megalin excretion is linked with the pathogenesis of diabetic nephropathy. Diabetes 2017; 66(5): 1391-404.7）Yamanouchi S, Kimata T, Kino J, Kitao T, Suruda C, Tsuji S, et al. Urinary C-megalin for screening of renal scarring in children after febrile urinary tract infection. Pediatr Res 2018; 83(3): 662-8.8）Kanzaki G, Puelles VG, Cullen-McEwen KA, Hoy WE, Okabayashi Y, Tsuboi N, et al. New insights on glomerular hyperfiltration: a Japanese autopsy study. JCI Insight 2017; 2(19): 94334.9）Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323-34.10）Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J 2015; 62(1): 77-86.11）Malatialli S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008; 2008: 305403.12）Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5(8): 610-21.13）Nunoi K, Sato Y, Kaku K, Yoshida A, Suganami H. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinol Diabetes Metab 2018; 1(2): e00015.SGLT2阻害薬による腎保護作用機序と尿中コンパニオン診断法の検討153
元のページ ../index.html#167